Publication: 2145

Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (Alliance).
   Google Scholar   
Citation:
J Clin Oncol vol 32 (15_suppl) e16061
Meeting Instance:
ASCO 2014
Year:
2014
Type:
Abstract
Sub type:
Published Only
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
2176   3894  
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                         
Networks:
 
Study
CALGB-90401
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: